Instrument Inactif

Communiqués Neuralstem, Inc. Nyse

Actions

US64127R3021

Cours en clôture Nyse Autres places de cotation
- ^USD	-

21/06	Palisade Bio fait le point sur l'avancement de sa collaboration stratégique avec Strand Life Sciences	CI
11/06	Palisade Bio annonce un avis d'admissibilité pour un brevet canadien couvrant son principal produit candidat, PALI-2108	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Palisade Bio to Participate in the Virtual Investor Closing Bell Series	24/06	AQ
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences	21/06	AQ
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108	11/06	AQ
Palisade Bio to Present at the Virtual Investor Pitch Conference	10/06	AQ
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models	21/05	AQ
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	AQ
Palisade Bio Appoints Margery Fischbein to its Board of Directors	07/05	AQ
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	02/05	AQ
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	01/05	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	24/04	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	17/04	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	16/04	AQ
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	11/04	AQ
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	10/04	AQ
Palisade Bio Announces 1-for-15 Reverse Stock Split	03/04	AQ
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update	27/03	AQ
Palisade Bio to Present at Digestive Disease Week (DDW) 2024	15/02	AQ
Palisade Bio Provides Corporate Update and Reiterates Guidance	13/02	AQ
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members	08/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Neuralstem, Inc. Nyse

Actions

US64127R3021

Communiqués

Filtres